Key clinical point: Researchers hope that genetic analyses could eventually point to prostate cancer patients who might benefit from statin use.
Major finding: Long-term statin users had lower odds of having a pTEN-null tumor (hazard ratio, 0.42), which is associated with worse outcomes.
Study details: Retrospective analysis of 5,792 diagnoses of prostate cancer among 44,076 men.
Disclosures: The study was funded by the Irish Cancer Society, the John Fitzpatrick Fellowship, and the National Cancer Institute. Dr. Allott reported no relevant financial relationships.
Source: Allott E et al. AUA 2018, Abstract MP21-01.
Allott E et al. AUA 2018 (annual meeting of the American Urological Association), Abstract MP21-01.
This Week's Must Reads
Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44. https://doi.org/10.1016/j.ijrobp.2018.09.005
TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885
Thrombolysis for acute ischemic stroke safe in GI malignancy, Inohara T et al. Circulation. 2018 Nov 6;138[suppl 1], Abstract A12291
Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04
Outcomes better in TNBC with adjuvant chemotherapy within 30 days of surgery, Morante Z et al., SABCS 2018 Abstract GS2-05
Must Reads in Genitourinary Cancer
Treating prostate with radiotherapy boosts survival in advanced prostate cancer, Parker C et al. ESMO 2018, Abstract LBA5_PR
Leptin expression may aid in differentiation of renal lesions, Gobe G et al. Pathology. 2018 Aug;50(5):504-10
Hypofractionated radiation offers 'tailored treatment' approach to RCC mets, Felice F et al. Crit Rev Oncol Hematol. 2018 Aug 1. doi: 10.1016/j.critrevonc.2018.06.002.
Concern over SREs rises with increasing incidence of metastatic RCC, Umer M et al. Ann Med Surg. 2018 Jan 21. doi: 10.1016/j.amsu.2018.01.002
Radioactive agent approved for adrenal tumors, FDA approves iobenguane I 131 injection (Azedra) for IV use for the treatment of pheochromocytoma or paraganglioma.